Fixed-Dose combinations of renin-angiotensin system inhibitors and calcium channel blockers in the treatment of hypertension: A comparison of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors

Medicine (United States)

Volumn 94, Issue 51, 2015, Pages

  Hsiao, Fu Chih ^a   Tung, Ying Chang ^a   Chou, Shing Hsien ^b   Wu, Lung Sheng ^b   Lin, Chia Pin ^b   Wang, Chun Li ^b   Lin, Yu Sheng ^b   Chang, Chee Jen ^a   Chu, Pao Hsien ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIALYSIS; DRUG EFFECT; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPENSITY SCORE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; SURVIVAL RATE; AGED; DRUG COMBINATION; INSURANCE; SURVIVAL ANALYSIS;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84952645541     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002355     Document Type: Article

References (62)

1. Angell SY, De Cock KM, Frieden TR. A public health approach to global management of hypertension. Lancet. 2015;385:825-827
2. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275:1571-1576
3. Mulrow CD, Pignone M. What are the elements of good treatment for hypertension? BMJ. 2001;322:1107-1109
4. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959-968
5. Guo F, He D, Zhang W, et al. Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010. J Am Coll Cardiol. 2012;60:599-606
6. Su TC, Bai CH, Chang HY, et al. Evidence for improved control of hypertension in Taiwan: 1993-2002. J Hypertens. 2008;26:600-606
7. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520
8. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press. 2014;23:3-16
9. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol. 2015;65:1998-2038
10. Chiang CE, Wang TD, Ueng KC, et al. 2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension. J Chin Med Assoc. 2015;78: 1-47
11. Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4:90-98
12. Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens (Greenwich). 2009;11:376-382
13. Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59:1124-1131
14. Tung YC, Lin YS, Wu LS, et al. Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan. J Clin Hypertens (Greenwich). 2015;17:51-58
15. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428
16. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol. 1995;40:141-144
17. Ng LP, Goh PS. Incidence of discontinuation of angiotensinconverting enzyme inhibitors due to cough, in a primary healthcare centre in Singapore. Singapore Med J. 2014;55:146-149
18. Hsu CN, Wang TD. Secular trends in prescription patterns of singlepill combinations of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker plus a thiazide diuretic for hypertensive patients in Taiwan. Acta Cardiol Sin. 2013;29:49-55
19. Boyko EJ, Barr EL, Zimmet PZ, et al. Two-hour glucose predicts the development of hypertension over 5 years: the AusDiab study. J Hum Hypertens. 2008;22:168-176
20. Chiang CH, Huang WC, Yang JS, et al. Five-year outcomes after acute myocardial infarction in patients with and without diabetes mellitus in Taiwan, 1996-2005. Acta Cardiol Sin. 2013;29:387-394
21. Chou SH, Tung YC, Lin YS, et al. Major adverse cardiovascular events in treated periodontitis: a population-based follow-up study from Taiwan. PloS One. 2015;10:e0130807
22. Lin YS, Liu PH, Wu LS, et al. Major adverse cardiovascular events in adult congenital heart disease: a population-based follow-up study from Taiwan. BMC Cardiovasc Disord. 2014;14:38
23. Lin YS, Tang CH, Yang CY, et al. Effect of pre-eclampsiaeclampsia on major cardiovascular events among peripartum women in Taiwan. Am J Cardiol. 2011;107:325-330
24. Tang CH, Wu CS, Lee TH, et al. Preeclampsia-eclampsia and the risk of stroke among peripartum in Taiwan. Stroke. 2009;40:1162-1168
25. Wu LS, Tang CH, Lin YS, et al. Major adverse cardiovascular events and mortality in systemic lupus erythematosus patients after successful delivery: a population-based study. Am J Med Sci. 2014;347:42-49
26. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11: 44-47
27. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761-2788
28. OGara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362-425
29. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810-1852
30. Ferrari R, Boersma E. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review. Expert Rev Cardiovasc Ther. 2013;11:705-717
31. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-Analysis. JAMA Intern Med. 2014;174:773-785
32. Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 2004;329:828
33. Investigators O, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559
34. McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol. 2006;47:726-733
35. Probstfield JL, OBrien KD. Progression of cardiovascular damage: the role of renin-Angiotensin system blockade. Am J Cardiol. 2010;105(1 Suppl):10A-20A.
36. Lee VC, Rhew DC, Dylan M, et al. Meta-Analysis: angiotensinreceptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med. 2004;141:693-704
37. Andersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int. 2000;57:601-606
38. Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. 2000;58:762-769
39. Blood Pressure Lowering Treatment Trialists CollaborationTurnbull F, Neal B, et al. . Blood pressure-dependent and independent effects of agents that inhibit the renin-Angiotensin system. J Hypertens. 2007;25:951-958
40. Abuissa H, Jones PG, Marso SP, et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-Analysis of randomized clinical trials. J Am Coll Cardiol. 2005;46:821-826
41. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:16-29
42. Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014;8:CD009096
43. Savarese G, Costanzo P, Cleland JG, et al. A meta-Analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013;61:131-142
44. Baumhakel M, Bohm M. Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials. Vasc Health Risk Manag. 2011;7:391-397
45. Santulli G. Adrenal signaling in heart failure something more than a distant ships smoke on the horizon. Hypertension. 2014;63:215-216
46. Santulli G, Ciccarelli M, Trimarco B, et al. Physical activity ameliorates cardiovascular health in elderly subjects: the functional role of the beta adrenergic system. Front Physiol. 2013;4:209
47. Lymperopoulos A, Sturchler E, Bathgate-Siryk A, et al. Different potencies of angiotensin receptor blockers at suppressing adrenal beta-Arrestin1-dependent post-myocardial infarction hyperaldosteronism. J Am Coll Cardiol. 2014;64:2805-2806
48. Dabul S, Bathgate-Siryk A, Valero TR, et al. Suppression of adrenal betaarrestin1-dependent aldosterone production by ARBs: headto-head comparison. Sci Rep. 2015;5:8116
49. Wan XMP, Zhang X. A promising choice in hypertension treatment: fixed-dose combinations. Asian J Pharm Sci. 2014;9:7
50. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs. 2008;8:45-50
51. Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med. 2009;6:101-110
52. van Galen KA, Nellen JF, Nieuwkerk PT. The effect on treatment adherence of administering drugs as fixed-dose combinations versus as separate pills: systematic review and meta-Analysis. AIDS Res Treat. 2014;2014:967073
53. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906
54. Santulli G. Adrenal signaling in heart failure: something more than a distant ships smoke on the horizon. Hypertension. 2014;63: 215-216
55. Santulli G, Ciccarelli M, Trimarco B, et al. Physical activity ameliorates cardiovascular health in elderly subjects: the functional role of the beta adrenergic system. Front Physiol. 2013;4:209
56. Yamaguchi J, Ogawa H, Hagiwara N. Indication and advantage of combination therapy with angiotensin II receptor blocker (ARB) and calcium channel antagonist. Nihon Rinsho. 2011;69:2059-2063
57. Bobrie G, Investigators IAS. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase, prospective, randomized, open-label with blindedend point evaluation study. Clin Ther. 2012;34:1720-1734e1723
58. Bobrie G, Investigators ICS. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5mg monotherapy: a multicenter, phase, prospective, randomized, open-label with blinded-end point evaluation study. Clin Ther. 2012;34: 1705-1719
59. Lanni F, Santulli G, Izzo R, et al. The Pl(A1/A2) polymorphism of glycoproteina and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients. J Hypertens. 2007;25:551-556
60. Galasso G, Santulli G, Piscione F, et al. The GPIIIA PlA2 polymorphism is associated with an increased risk of cardiovascular adverse events. BMC Cardiovasc Disord. 2010;10:41
61. Santulli G, Cipolletta E, Sorriento D, et al. CaMK4 gene deletion induces hypertension. J Am Heart Assoc. 2012;1:e001081
62. Santulli G, Trimarco B, Iaccarino G. G-protein-coupled receptor kinase 2 and hypertension: molecular insights and pathophysiological mechanisms. High Blood Press Cardiovasc Prev. 2013;20:5-12